10.6084/m9.figshare.11665008.v1 Jiahang Mo Jiahang Mo Xiao Hu Xiao Hu Lihu Gu Lihu Gu Bangsheng Chen Bangsheng Chen Parikshit Khadaroo Parikshit Khadaroo Zefeng Shen Zefeng Shen Lei Dong Lei Dong Yuqi Lv Yuqi Lv Marylin Chitumba Marylin Chitumba Jiequan Liu Jiequan Liu MOESM3 of Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis Springer Nature 2020 Smoking Immunotherapy Immune checkpoint inhibitors Anti-PD-1/PD-L1 Meta-analysis 2020-01-21 05:11:50 Figure https://springernature.figshare.com/articles/figure/MOESM3_of_Smokers_or_non-smokers_who_benefits_more_from_immune_checkpoint_inhibitors_in_treatment_of_malignancies_An_up-to-date_meta-analysis/11665008 Additional file 3: Figure S3. Forest plot of the long-term prognostic outcomes of anti-PD-1/PD-L1 monotherapy in NSCLC (Non-smoker vs. Smoker), PNon-smoker=0.921, PSmoker<0.001.